Molecular Insight Pharmaceuticals Buying Texas Facility For $3 Million

Biotechnology company Molecular Insight Pharmaceuticals is purchasing a manufacturing and warehouse facility for $3 million to make molecular imaging agents and other products.

CAMBRIDGE, Mass. (AP) - Biotechnology company Molecular Insight Pharmaceuticals Inc. said Thursday it will buy a manufacturing and warehouse facility for $3 million.

The company is buying the facility, located in Denton, Texas, from NeoRx Manufacturing Group Inc., a subsidiary of Poniard Pharmaceuticals Inc.

Molecular Insight said it will use the facility to make molecular imaging agents including Zemiva and Trofex and other products including Azedra, Onalta and Solazed.

The facility contains more than 80,000 square feet of space.